银屑病生物制剂治疗选择的定量评估:系统综述与网络荟萃分析
该研究通过系统检索 MEDLINE、PubMed、Embase 和 Cochrane 数据库,纳入 41 项随机对照试验(共 20,561 名参与者),采用网络荟萃分析比较已获批生物制剂之间及与甲氨蝶呤或安慰剂的疗效与耐受性。结果显示所有生物制剂在 3-4 个月时均优于安慰剂或甲氨蝶呤;聚类分析表明阿达木单抗、司库奇尤单抗和乌司奴单抗在高疗效与耐受性方面相当,而依奇珠单抗和英夫利西单抗疗效极高但耐受性较差。
要点
- 所有纳入的生物制剂在3-4个月时均优于安慰剂或甲氨蝶呤。
- 阿达木单抗、司库奇尤单抗和乌司奴单抗在高疗效和耐受性上相当。
- 依奇珠单抗和英夫利西单抗疗效极高但耐受性较差。
核心结论
- 生物制剂之间可区分疗效与耐受性,有助于临床实践和决策。
研究设计与样本
- 系统综述与网络荟萃分析,纳入41项随机对照试验共20,561名参与者。
- 检索MEDLINE、PubMed、Embase和Cochrane数据库,比较已获批生物制剂之间及与甲氨蝶呤或安慰剂。
- 结合层次聚类分析综合考虑疗效与耐受性多结局,并评估研究质量、异质性和不一致性。
主要发现
- 所有纳入的生物制剂在3-4个月时均优于安慰剂或甲氨蝶呤。
- 聚类分析显示阿达木单抗、司库奇尤单抗和乌司奴单抗在高疗效和耐受性方面相当。
- 依奇珠单抗和英夫利西单抗以极高疗效但耐受性较差为特征。
临床怎么用
- 结果可帮助临床医生和指南制定者在生物制剂间进行选择。
- 需结合真实世界长期安全性和有效性数据综合考量。
局限性
- 缺乏长期对照数据,分析仅限于短期结局。
- 试验表现可能不等同于真实世界表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple biologic treatments are licensed for psoriasis. The lack of head-to-head randomized controlled trials makes choosing between them difficult for patients, clinicians, and guideline developers. To establish their relative efficacy and tolerability, we searched MEDLINE, PubMed, Embase, and Cochrane for randomized controlled trials of licensed biologic treatments for skin psoriasis. We performed a network meta-analysis to identify direct and indirect evidence comparing biologics with one another, methotrexate, or placebo. We combined this with hierarchical cluster analysis to consider multiple outcomes related to efficacy and tolerability in combination for each treatment. Study quality, heterogeneity, and inconsistency were evaluated. Direct comparisons from 41 randomized controlled trials (20,561 participants) were included. All included biologics were efficacious compared with placebo or methotrexate at 3-4 months. Overall, cluster analysis showed adalimumab, secukinumab, and ustekinumab were comparable in terms of high efficacy and tolerability. Ixekizumab and infliximab were differentiated by very high efficacy but poorer tolerability. The lack of longer term controlled data limited our analysis to short-term outcomes. Trial performance may not equate to real-world performance, and so results need to be considered alongside real-world, long-term safety and effectiveness data. These data suggest that it is possible to discriminate between biologics to inform clinical practice and decision making (PROSPERO 2015:CRD42015017538).
引用
- Jabbar-Lopez ZK, Yiu ZZN, Ward V, et al. Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. J Invest Dermatol. 2017. PMID: 28457908. doi:10.1016/j.jid.2017.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。